US FDA considering striking statin use from labeling of Abbott's Trilipix
This article was originally published in Scrip
Executive Summary
The US FDA is mulling over whether use of a statin should be dropped from the approved indications of Abbott's fibrate drug Trilipix (fenofibric acid) in light of a study that found no difference in effectiveness in reducing heart attacks after adding Merck's Zocor (simvastatin) to fenofibrate – a drug similar to Trilipix – but actually increased the risk of a major adverse cardiac event in women.